The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance
Open accessAbstract
Tumor heterogeneity is one of the hallmarks of cancer and a challenge in the field of oncology. Tumor heterogeneity is the main cause of drug resistance, leading to therapeutic failure. Mechanically, tumor heterogeneity either directly affects therapeutic targets or shapes the tumor microenvironment (TME) by defining transcriptomic and phenotypic profiles to influence drug resistance. Tumor heterogeneity evolves spatially and temporally during tumor development, leading to the constant reprogramming of the TME. Advances in molecular profiling technologies and precision oncology platforms have allowed us to uncover the impact of tumor heterogeneity on drug resistance in the context of the TME. In this review, we focus on the processes during which genomic mutations drive tumor heterogeneity and the mechanisms through which tumor heterogeneity reprograms the TME to affect drug resistance and patient prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Causal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
Visualization and analysis of gene expression in tissue sections by spatial transcriptomics
Ståhl, P. L., Salmén, F., Vickovic, S., Lundmark, A., Navarro, J. F., Magnusson, J., Giacomello, S., Asp, M., Westholm, J. O., Huss, M., et al. (2016) · Science · doi:10.1126/science.aaf2403 · Cited by 3,834
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Pan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
Anderson, N. M., & Simon, M. C. (2020) · Current Biology · doi:10.1016/j.cub.2020.06.081 · Cited by 2,718
Puram, S. V., Tirosh, I., Parikh, A. S., Patel, A. P., Yizhak, K., Gillespie, S., Rodman, C., Luo, C. L., Mroz, E. A., Emerick, K. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.044 · Cited by 2,557
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J. Y., Zhang, Q., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.035 · Cited by 2,152
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma
Zhang, Q., He, Y., Luo, N., Patel, S. J., Han, Y., Gao, R., Modak, M., Carotta, S., Haslinger, C., Kind, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.003 · Cited by 1,624
A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells
Cheng, S., Li, Z., Gao, R., Xing, B., Gao, Y., Yang, Y., Qin, S., Zhang, L., Ouyang, H., Du, P., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.010 · Cited by 1,601
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer
Zhang, L., Li, Z., Skrzypczynska, K. M., Fang, Q., Zhang, W., O’Brien, S. A., He, Y., Wang, L., Zhang, Q., Kim, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.048 · Cited by 1,526
Haslam, A., & Prasad, V. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2535 · Cited by 1,413
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
Bagaev, A., Kotlov, N., Nomie, K., Svekolkin, V., Gafurov, A., Isaeva, O., Osokin, N., Kozlov, I., Frenkel, F., Gancharova, O., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.014 · Cited by 1,302
Roles of IFN-γ in tumor progression and regression: A review
Jorgovanovic, D., Song, M., Wang, L., & Zhang, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00228-x · Cited by 1,234
Jiang, Y.-Z., Ma, D., Suo, C., Shi, J., Xue, M., Hu, X., Xiao, Y., Yu, K.-D., Liu, Y.-R., Yu, Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.001 · Cited by 1,062
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
Blass, E., & Ott, P. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00460-2 · Cited by 1,042
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
Marusyk, A., Janiszewska, M., & Polyak, K. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.007 · Cited by 1,009
Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq
Venteicher, A. S., Tirosh, I., Hebert, C., Yizhak, K., Neftel, C., Filbin, M. G., Hovestadt, V., Escalante, L. E., Shaw, M. L., Rodman, C., et al. (2017) · Science · doi:10.1126/science.aai8478 · Cited by 1,004
An Immune Atlas of Clear Cell Renal Cell Carcinoma
Chevrier, S., Levine, J. H., Zanotelli, V. R. T., Silina, K., Schulz, D., Bacac, M., Ries, C. H., Ailles, L., Jewett, M. A. S., Moch, H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.016 · Cited by 1,004
Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969
Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer.
Kieffer, Y., Hocine, H. R., Gentric, G., Pelon, F., Bernard, C., Bourachot, B., Lameiras, S., Albergante, L., Bonneau, C., Guyard, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1384 · Cited by 910
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
De Henau, O., Rausch, M., Winkler, D., Campesato, L. F., Liu, C., Cymerman, D. H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 860
Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer
Ma, L., Hernandez, M. O., Zhao, Y., Mehta, M., Tran, B., Kelly, M., Rae, Z., Hernandez, J. M., Davis, J. L., Martin, S. P., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.007 · Cited by 844
Intratumoral heterogeneity in cancer progression and response to immunotherapy
Vitale, I., Shema, E., Loi, S., & Galluzzi, L. (2021) · Nature Medicine · doi:10.1038/s41591-021-01233-9 · Cited by 826
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Circulating tumour cells in cancer patients: challenges and perspectives
Pantel, K., & Alix-Panabières, C. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.001 · Cited by 815
Wu, F., Fan, J., He, Y., Xiong, A., Yu, J., Li, Y., Zhang, Y., Zhao, W., Zhou, F., Li, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22801-0 · Cited by 796
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
Wagner, J., Rapsomaniki, M. A., Chevrier, S., Anzeneder, T., Langwieder, C., Dykgers, A., Rees, M., Ramaswamy, A., Muenst, S., Soysal, S. D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.005 · Cited by 790
Toward understanding and exploiting tumor heterogeneity
Alizadeh, A. A., Aranda, V., Bardelli, A., Blanpain, C., Bock, C., Borowski, C., Caldas, C., Califano, A., Doherty, M., Elsner, M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3915 · Cited by 746
The clinical role of the TME in solid cancer
Giraldo, N. A., Sanchez-Salas, R., Peske, J. D., Vano, Y., Becht, E., Petitprez, F., Validire, P., Ingels, A., Cathelineau, X., Fridman, W. H., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0327-z · Cited by 732
Neoantigen vaccine: an emerging tumor immunotherapy
Peng, M., Mo, Y., Wang, Y., Wu, P., Zhang, Y., Xiong, F., Guo, C., Wu, X., Li, Y., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1055-6 · Cited by 700
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.004 · Cited by 700
Chen, Z., Zhou, L., Liu, L., Hou, Y., Xiong, M., Yang, Y., Hu, J., & Chen, K. (2020) · Nature Communications · doi:10.1038/s41467-020-18916-5 · Cited by 694
Zhou, Y., Yang, D., Yang, Q., Lv, X., Huang, W., Zhou, Z., Wang, Y., Zhang, Z., Yuan, T., Ding, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20059-6 · Cited by 672
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Twomey, J. D., & Zhang, B. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00574-0 · Cited by 657
Classification of triple-negative breast cancers based on Immunogenomic profiling
He, Y., Jiang, Z., Chen, C., & Wang, X. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1002-1 · Cited by 624
Zhang, M., Yang, H., Wan, L., Wang, Z., Wang, H., Ge, C., Liu, Y., Hao, Y., Zhang, D., Shi, G., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.05.039 · Cited by 605
The hallmarks of successful anticancer immunotherapy
Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575
Schumacher, T. N., Scheper, W., & Kvistborg, P. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053402 · Cited by 574
Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity
Berglund, E., Maaskola, J., Schultz, N., Friedrich, S., Marklund, M., Bergenstråhle, J., Tarish, F., Tanoglidi, A., Vickovic, S., Larsson, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04724-5 · Cited by 562
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Lu, X., Horner, J. W., Paul, E., Shang, X., Troncoso, P., Deng, P., Jiang, S., Chang, Q., Spring, D. J., Sharma, P., et al. (2017) · Nature · doi:10.1038/nature21676 · Cited by 547
Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes
Dentro, S. C., Leshchiner, I., Haase, K., Tarabichi, M., Wintersinger, J., Deshwar, A. G., Yu, K., Rubanova, Y., Macintyre, G., Demeulemeester, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.009 · Cited by 533
Vascular Endothelial Growth Factor Signaling in Hypoxia and Inflammation
Ramakrishnan, S., Anand, V., & Roy, S. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9531-7 · Cited by 442
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
Gruosso, T., Gigoux, M., Manem, V. S. K., Bertos, N., Zuo, D., Perlitch, I., Saleh, S. M. I., Zhao, H., Souleimanova, M., Johnson, R. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci96313 · Cited by 439
Chan, J. M., Quintanal-Villalonga, Á., Gao, V. R., Xie, Y., Allaj, V., Chaudhary, O., Masilionis, I., Egger, J., Chow, A., Walle, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.008 · Cited by 434
Hornburg, M., Desbois, M., Lu, S., Guan, Y., Lo, A. A., Kaufman, S., Elrod, A., Lotstein, A., DesRochers, T. M., Munoz-Rodriguez, J. L., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.004 · Cited by 383
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
Wolf, Y., Bartok, O., Patkar, S., Eli, G. B., Cohen, S., Litchfield, K., Levy, R., Jiménez-Sánchez, A., Trabish, S., Lee, J. S., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.032 · Cited by 380
Loeuillard, E., Yang, J., Buckarma, E., Wang, J., Liu, Y., Conboy, C., Pavelko, K. D., Li, Y., O’Brien, D., Wang, C., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137110 · Cited by 369
Stewart, C. A., Gay, C. M., Xi, Y., Sivajothi, S., Sivakamasundari, V., Fujimoto, J., Bolisetty, M., Hartsfield, P. M., Balasubramaniyan, V., Chalishazar, M. D., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0020-z · Cited by 366
Leader, A. M., Grout, J. A., Maier, B. B., Nabet, B. Y., Park, M. D., Tabachnikova, A., Chang, C., Walker, L., Lansky, A., Le Berichel, J., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.009 · Cited by 365
Tumor evolution: Linear, branching, neutral or punctuated?
Davis, A., Gao, R., & Navin, N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.01.003 · Cited by 352
Liquid Biopsy: General Concepts
Poulet, G., Massias, J., & Taly, V. (2019) · Acta Cytologica · doi:10.1159/000499337 · Cited by 332
Kim, I. S., Gao, Y., Welte, T., Wang, H., Liu, J., Janghorban, M., Sheng, K., Niu, Y., Goldstein, A., Zhao, N., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0373-7 · Cited by 327
Ho, D. W.-H., Tsui, Y.-M., Chan, L.-K., Sze, K. M.-F., Zhang, X., Cheu, J. W.-S., Chiu, Y.-T., Lee, J. M.-F., Chan, A. C.-Y., Cheung, E. T.-Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24010-1 · Cited by 324
Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment
Sun, X.-X., & Yu, Q. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.92 · Cited by 318
Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation
Guo, S., & Deng, C.-X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.25720 · Cited by 315
Self-citationYamazaki, C. M., Yamaguchi, A., Anami, Y., Xiong, W., Otani, Y., Lee, J., Ueno, N. T., Zhang, N., An, Z., & Tsuchikama, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23793-7 · Cited by 309
An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
Tong, J. T. W., Harris, P. W. R., Brimble, M. A., & Kavianinia, I. (2021) · Molecules · doi:10.3390/molecules26195847 · Cited by 287
Spatially resolved transcriptomics reveals the architecture of the tumor-microenvironment interface
Hunter, M. V., Moncada, R., Weiss, J. M., Yanai, I., & White, R. M. (2021) · Nature Communications · doi:10.1038/s41467-021-26614-z · Cited by 285
Neoantigen: A New Breakthrough in Tumor Immunotherapy
Zhang, Z., Lu, M., Qin, Y., Gao, W., Tao, L., Su, W., & Zhong, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672356 · Cited by 284
Pembrolizumab for the treatment of non-small cell lung cancer
Lim, S. H., Sun, J.-M., Lee, S.-H., Ahn, J. S., Park, K., & Ahn, M.-J. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1145652 · Cited by 282
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Minn, A. J., & Wherry, E. J. (2016) · Cell · doi:10.1016/j.cell.2016.03.031 · Cited by 271
Spatial genomics enables multi-modal study of clonal heterogeneity in tissues
Zhao, T., Chiang, Z. D., Morriss, J. W., LaFave, L. M., Murray, E. M., Del Priore, I., Meli, K., Lareau, C. A., Nadaf, N. M., Li, J., et al. (2022) · Nature · doi:10.1038/s41586-021-04217-4 · Cited by 268
Clonal Decomposition and DNA Replication States Defined by Scaled Single-Cell Genome Sequencing
Laks, E., McPherson, A., Zahn, H., Lai, D., Steif, A., Brimhall, J., Biele, J., Wang, B., Masud, T., Ting, J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.026 · Cited by 257
Sucker, A., Zhao, F., Pieper, N., Heeke, C., Maltaner, R., Stadtler, N., Real, B., Bielefeld, N., Howe, S., Weide, B., et al. (2017) · Nature Communications · doi:10.1038/ncomms15440 · Cited by 252
Antibody–drug conjugates in solid tumors: a look into novel targets
Criscitiello, C., Morganti, S., & Curigliano, G. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01035-z · Cited by 250
Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation
Yu, M., Peng, Z., Qin, M., Liu, Y., Wang, J., Zhang, C., Lin, J., Dong, T., Wang, L., Li, S., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.010 · Cited by 250
Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine
Lipinski, K. A., Barber, L. J., Davies, M. N., Ashenden, M., Sottoriva, A., & Gerlinger, M. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2015.11.003 · Cited by 248
Kowanetz, M., Zou, W., Gettinger, S. N., Koeppen, H., Kockx, M., Schmid, P., Kadel, E. E., Wistuba, I., Chaft, J., Rizvi, N. A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802166115 · Cited by 235
Dafni, U., Tsourti, Z., Vervita, K., & Peters, S. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.029 · Cited by 221
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Rinnerthaler, G., Gampenrieder, S. P., & Greil, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051115 · Cited by 220
Samstein, R. M., Krishna, C., Ma, X., Pei, X., Lee, K.-W., Makarov, V., Kuo, F., Chung, J., Srivastava, R. M., Purohit, T. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00139-8 · Cited by 219
Resistance to Antibody–Drug Conjugates
García-Alonso, S., Ocaña, A., & Pandiella, A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3671 · Cited by 208
Xing, X., Yang, F., Huang, Q., Guo, H., Li, J., Qiu, M., Bai, F., & Wang, J. (2021) · Science Advances · doi:10.1126/sciadv.abd9738 · Cited by 205
Zhang, Y., Zuo, C., Liu, L., Hu, Y., Yang, B., Qiu, S., Li, Y., Cao, D., Ju, Z., Ge, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.023 · Cited by 198
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Wang, Z., & Wu, X. (2020) · Cancer Medicine · doi:10.1002/cam4.3410 · Cited by 195
Wan, C., Keany, M. P., Dong, H., Al-Alem, L. F., Pandya, U. M., Lazo, S., Boehnke, K., Lynch, K. N., Xu, R., Zarrella, D. T., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1674 · Cited by 193
Surveying brain tumor heterogeneity by single-cell RNA-sequencing of multi-sector biopsies
Yu, K., Hu, Y., Wu, F., Guo, Q., Qian, Z., Hu, W., Chen, J., Wang, K., Fan, X., Wu, X., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa099 · Cited by 189
Roper, N., Brown, A.-L., Wei, J. S., Pack, S., Trindade, C., Kim, C., Restifo, O., Gao, S., Sindiri, S., Mehrabadi, F., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100007 · Cited by 180
Hu, J., Chen, Z., Bao, L., Zhou, L., Hou, Y., Liu, L., Xiong, M., Zhang, Y., Wang, B., Tao, Z., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.023 · Cited by 179
Germline genetic contribution to the immune landscape of cancer
Sayaman, R. W., Saad, M., Thorsson, V., Hu, D., Hendrickx, W., Roelands, J., Porta-Pardo, E., Mokrab, Y., Farshidfar, F., Kirchhoff, T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.011 · Cited by 179
Next-generation computational tools for interrogating cancer immunity
Finotello, F., Rieder, D., Hackl, H., & Trajanoski, Z. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0166-7 · Cited by 162
A narrative review of tumor heterogeneity and challenges to tumor drug therapy
Zhu, L., Jiang, M., Wang, H., Sun, H., Zhu, J., Zhao, W., Fang, Q., Yu, J., Chen, P., Wu, S., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1948 · Cited by 162
Self-citationDoi, T., Ishikawa, T., Okayama, T., Oka, K., Mizushima, K., Yasuda, T., Sakamoto, N., Katada, K., Kamada, K., Uchiyama, K., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5399 · Cited by 150
Williams, J. B., Li, S., Higgs, E. F., Cabanov, A., Wang, X., Huang, H., & Gajewski, T. F. (2020) · Nature Communications · doi:10.1038/s41467-020-14290-4 · Cited by 141
Winterhoff, B. J. N., Maile, M., Mitra, A., Sebe, A., Bazzaro, M., Geller, M. A., Abrahante, J. E., Klein, M. E., Hellweg, R., Mullany, S. A., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.01.015 · Cited by 137
From bench to bedside: Single-cell analysis for cancer immunotherapy
Davis-Marcisak, E. F., Deshpande, A. M., Stein-O’Brien, G., Ho, W. J., Laheru, D. A., Jaffee, E. M., Fertig, E. J., & Kagohara, L. T. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.004 · Cited by 133
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A. K., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · eScholarship (California Digital Library) · Cited by 120
Schmelz, K., Toedling, J., Huska, M. R., Cwikla, M. C., Kruetzfeldt, L.-M., Proba, J., Ambros, P. F., Ambros, I. M., Boral, Ş., Lodrini, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26870-z · Cited by 110
Munari, E., Zamboni, G., Marconi, M., Sommaggio, M., Brunelli, M., Martignoni, G., Netto, G. J., Moretta, F., Mingari, M. C., Salgarello, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21485 · Cited by 109
Grossman, J. E., Vasudevan, D., Joyce, C. E., & Hildago, M. (2021) · Oncogene · doi:10.1038/s41388-020-01611-6 · Cited by 107
Raynaud, F., Mina, M., Tavernari, D., & Ciriello, G. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007669 · Cited by 106
Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomesPreprint
Dentro, S. C., Leshchiner, I., Haase, K., Tarabichi, M., Wintersinger, J. A., Deshwar, A. G., Yu, K., Rubanova, Y., Macintyre, G., Demeulemeester, J., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/312041 · Cited by 104
Intratumor heterogeneity defines treatment‐resistant HER 2+ breast tumors
Rye, I. H., Trinh, A. C., Sætersdal, A. B., Nebdal, D. J. H., Lingjærde, O. C., Almendro, V., Polyák, K., Børresen‐Dale, A., Helland, Å., Markowetz, F. M., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12375 · Cited by 103
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
Luo, N., Formisano, L., Ericsson, P. I. G., Sanchez, V. M., Dean, P. T., Opalenik, S. R., Sanders, M. E., Cook, R. S., Arteaga, C. L., Johnson, D. B., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1438106 · Cited by 95
The oncology market for antibody–drug conjugates
do Pazo, C., Nawaz, K., & Webster, R. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/d41573-021-00054-2 · Cited by 93
Zhou, S., Huang, Y., Liu, H., Zhou, X., Yuan, M., Hou, F., Wang, L., & Jiang, W. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.12.018 · Cited by 78
Sundar, R., Liu, D. H. W., Hutchins, G. G. A., Slaney, H., Silva, A. N. S., Oosting, J., Hayden, J. D., Hewitt, L. C., Ng, C. C. Y., Mangalvedhekar, A. N., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320805 · Cited by 77
Annunziato, S., de Ruiter, J. R., Henneman, L., Brambillasca, C. S., Lutz, C., Vaillant, F., Ferrante, F., Drenth, A. P., van der Burg, E., Siteur, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08301-2 · Cited by 73
The Significance of Liquid Biopsy in Pancreatic Cancer
Qi, Z.-H., Xu, H., Zhang, S.-R., Xu, J.-Z., Li, S., Gao, H.-L., Jin, W., Wang, W.-Q., Wu, C., Ni, Q., et al. (2018) · Journal of Cancer · doi:10.7150/jca.24591 · Cited by 60
Yuan, X. F., Wang, J., Huang, Y., Shangguan, D., & Zhang, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643692 · Cited by 60
Deng, W., Ma, Y., Su, Z., Liu, Y., Liang, P., Huang, C., Liu, X., Shao, J., Zhang, Y., Zhang, K., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.12.003 · Cited by 51
Lv, J., Shi, Q., Han, Y., Li, W., Liu, H., Zhang, J., Niu, C., Gao, G., Fu, Y., Zhi, R., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04380-6 · Cited by 46
Xing, F., Liu, Y., Huang, S., Lyu, X., Su, S. M., Chan, U. I., Wu, P., Yan, Y., Ai, N., Li, J., et al. (2021) · Theranostics · doi:10.7150/thno.59533 · Cited by 41
Self-citationRecent Advances in Liquid Biopsy in Precision Oncology Research
Sato, Y., Matoba, R., & Kato, K. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00804 · Cited by 40
Cancer Cells Resistance Shaping by Tumor Infiltrating Myeloid Cells
Domagala, M., Laplagne, C., Leveque, E., Laurent, C., Fournié, J., Espinosa, É., & Poupot, M. (2021) · Cancers · doi:10.3390/cancers13020165 · Cited by 38
Antibody–drug conjugates for lung cancer in the era of personalized oncology
Ricciuti, B., Lamberti, G., Andrini, E., Genova, C., Giglio, A. D., Bianconi, V., Sahebkar, A., Chiari, R., & Pirro, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.024 · Cited by 35
Conteduca, V., Ku, S., Fernandez, L., Dago, A. E., Lee, J. S. H., Jendrisak, A., Slade, M. M., Gilbertson, C., Manohar, J., Sigouros, M., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00211-1 · Cited by 35
Nishimura, R., Okumura, Y., & Arima, N. (2007) · Breast Cancer · doi:10.1007/s12282-007-0014-z · Cited by 34
Catch my drift? Making sense of genomic intra-tumour heterogeneity
Sottoriva, A., Barnes, C. P., & Graham, T. A. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.12.003 · Cited by 34
Oulhen, M., Pawlikowska, P., Tayoun, T., Garonzi, M., Buson, G., Forcato, C., Manaresi, N., Aberlenc, A., Mezquita, L., Lécluse, Y., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00203-1 · Cited by 32
Spatially resolved transcriptomics reveals the architecture of the tumor/microenvironment interfacePreprint
Hunter, M. V., Moncada, R. M., Weiss, J. M., Yanai, I., & White, R. M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.05.368753 · Cited by 24
Decoding the genetic basis of anti-tumor immunity
Zheng, L., & Zhang, Z. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.005 · Cited by 5
Cited by
Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256
Notch receptor/ligand diversity: contribution to colorectal cancer stem cell heterogeneity
Brisset, M., Mehlen, P., Meurette, O., & Hollande, F. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1231416 · Cited by 20
Glycosylation in cancer: mechanisms, diagnostic markers, and therapeutic applications
Qusairy, Z., & Rada, M. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05303-1 · Cited by 16
Metadata
- Authors
- Zhang, A., Miao, K., Sun, H., & Deng, C.-X.
- Venue
- International Journal of Biological Sciences
- Publisher
- Ivyspring International Publisher
- Published
- 2022
- Volume
- 18
- Issue
- 7
- Pages
- 3019-3033
- ISSN
- 1449-2288 (ISSN-L)
- OpenAlex
- W4285288952
- Cited by
- 352
- References
- 123
- FWCI
- 21.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.